摘要
目的观察程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌的临床疗效及用药安全。方法选取2020年1月-2023年5月我院诊治的60例晚期非小细胞肺癌患者为研究对象,采用随机数字表法分为对照组和观察组,各30例。对照组采用常规紫彬醇联合顺铂化疗治疗,观察组在对照组基础上给予程序性死亡蛋白-1抑制剂治疗,比较两组临床疗效、细胞免疫指标(CD3^(+)、CD4^(+)、CD8^(+))、炎症因子水平[白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)]及不良反应发生率。结果观察组治疗总有效率为76.67%,高于对照组的46.67%(P<0.05);两组治疗后CD3^(+)、CD4^(+)均高于治疗前,CD8^(+)低于治疗前,且观察组CD3^(+)、CD4^(+)高于对照组,CD8^(+)低于对照组(P<0.05);两组治疗后IL-6、TNF-α水平均低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论晚期非小细胞肺癌采用程序性死亡蛋白-1抑制剂治疗的效果良好,可改善细胞免疫因子和炎症因子水平,且不增加不良反应发生风险。
Objective To observe the clinical efficacy and safety of programmed death protein-1 inhibitor in the treatment of advanced non-small cell lung cancer.Methods A total of 60 patients with advanced non-small cell lung cancer diagnosed and treated in our hospital from January 2020 to May 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 30 cases in each group.The control group was treated with conventional violet alcohol combined with cisplatin chemotherapy,and the observation group was treated with programmed death protein-1 inhibitor on the basis of the control group.The clinical efficacy,cellular immune indexes(CD3^(+),CD4^(+),CD8^(+)),inflammatory factor levels[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 76.67%,which was higher than 46.67%in the control group(P<0.05).After treatment,CD3^(+)and CD4^(+)in the two groups were higher than those before treatment,CD8^(+)was lower than that before treatment,and CD3^(+)and CD4^(+)in the observation group were higher than those in the control group,CD8^(+)was lower than that in the control group(P<0.05).After treatment,the levels of IL-6 and TNF-αin the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion Programmed death protein-1 inhibitor is effective in the treatment of advanced non-small cell lung cancer,which can improve the levels of cellular immune factors and inflammatory factors without increasing the risk of adverse reactions..
作者
徐怡英
XU Yi-ying(Department of Oncology and Hematology,the First People's Hospital of Longnan,Longnan 341700,Jiangxi,China)
出处
《医学信息》
2023年第23期115-117,121,共4页
Journal of Medical Information
关键词
程序性死亡蛋白-1抑制剂
晚期非小细胞肺癌
免疫功能
炎症因子
Programmed death protein-1 inhibitors
Advanced non-small cell lung cancer
Immune function
Inflammatory factors
